---
schema_version: "secwatch.filing_event.v1"
accession: "0001510964-22-000040"
form_type: "8-K"
ticker: "CVSI"
cik: "0001510964"
company_name: "CV Sciences, Inc."
filed_at: "2022-05-16T23:59:59+00:00"
generated_at: "2026-06-25T14:41:03.125255+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CV Sciences Q1 revenue $4.4M (-8% YoY); operating loss narrows to $1.5M on ERC benefit

## Summary
- Revenue $4.4M, down 8% from $4.8M in Q1 2021; units shipped up 3% offset by discounts and mix.
- Operating loss narrowed to $1.5M from $3.1M in Q1 2021; included $2.0M employee retention credit.
- Gross margin 26.0%, down from 32.4% in Q4 2021 sequentially; pressure from discounts/mix.
- Negative adjusted EBITDA $2.5M vs $2.3M a year ago; cash rose to $2.4M from $1.4M.
- Strategic review continues for possible merger/sale; launched new PlusCBD and OTC pain products.

## SEC filing metadata
- accession: 0001510964-22-000040
- form_type: 8-K
- ticker: CVSI
- cik: 0001510964
- company_name: CV Sciences, Inc.
- filed_at: 2022-05-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1510964/000151096422000040/0001510964-22-000040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1510964/000151096422000040/cvsi-20220516.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001510964-22-000040
- JSON: https://secwatch.observer/filing/0001510964-22-000040.json
- Plain text: https://secwatch.observer/filing/0001510964-22-000040.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.